ZDHHC7 and systemic lupus erythematosus: Under ZDHHC7 overexpression, the C508S mutant had a significant decrease of Alk14 labeling compared to WT, while other mutants (including MAVS C79F mutation, which alleviates systemic lupus erythematosus symptom due to abolished MAVS aggregation) (39) largely retained the modification (Fig. 2 A and B and SI Appendix, Fig. S4C), suggesting that C508 is the predominant palmitoylation site of MAVS catalyzed by ZDHHC7.